Meet with our product experts in one-on-one virtual sessions and get a deep insight into our API Pharma product offerings
Our experts will answer your questions, provide advice, and help you understand our product better.
Dr. Reddy’s Laboratories Ltd. is an integrated pharmaceutical company committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services & Active Ingredients, Global Generics, and Proprietary Products – Dr. Reddy’s is an active pharma API manufacturing company and pharmaceutical ingredient supplier for foremost formulators and offers a portfolio of products and services, including APIs, custom pharmaceutical services, generics, biosimilars, and differentiated formulations.
Our API pharma business caters to leading innovator and generic companies across the US, Europe, Latin America, Japan, Korea, and other emerging markets. We consistently deliver high-quality APIs with deep technical strengths in developing complex APIs such as steroids, peptides, complex long-chain synthesis, and oncology.
As a pharmaceutical API manufacturer, our major therapeutic areas focus on gastrointestinal, cardiovascular, diabetology, oncology, pain management, and dermatology. Dr. Reddy’s operates in global markets and is one of the top API manufacturers in the USA. As a pharma API supplier our major markets include – the USA, Europe, India, Russia, and other CIS countries.
About Dr. Reddy’s API Business
150+ APIs
8 Manufacturing
Sites
More than 1150 drug master files
across global markets
50+ Pipeline molecules
(Filed + under development)
State-of-the-art R&D centers
in India, U.K., U.S. & Netherlands
Over 1300+ research scientists
working on various projects
Our Achievements
11/11/2021
Dr. Reddy's API team is a 2021 winner in - API Supplier of the year at Global generics & Biosimilars awards
11/11/2021
The winner of the Corporate social responsibility (CSR) Initiative of the year at Global generics & Biosimilars Awards
10/11/2021
Dr. Reddy's at CPHI 2021
21/01/2021
Best Supply Chain Team of the Year - Pharma- 2021
03/11/2020
Dr. Reddy’s Laboratories wins “API Supplier of the Year” award at the Global Generics & Biosimilars Awards 2020
19/10/2020
Dr. Reddy's recognized at the CPhI Pharma Awards 2020 as the winner in the category of 'Excellence in Pharma: Sustainability'
Resources
Tofacitinib Citrate (Xeljanz) is an oral, small molecule drug used to treat adults with moderate to severe active rheumatoid arthritis (RA), active psoriatic arthritis, and moderate to severe ulce
Midostaurin is a small molecule that inhibits multiple receptor tyrosine kinases. In vitro biochemical or cellular assays have shown that Midostaurin or its major human active metabolites CGP62221
Pazopanib is a multi-tyrosine kinase inhibitor of vascular endothelial growth factor receptor (VEGFR)-1, VEGFR-2, VEGFR-3, platelet-derived growth factor receptor (PDGFR)-α and -β, fibroblast gr
Relugolix is a medication used for the treatment of advanced prostate cancer, endometriosis- associated pain, and uterine fibroids. It works by suppressing the production of hormones that stimulat
Tucatinib is a small molecule tyrosine kinase inhibitor that selectively targets human epidermal growth factor receptor 2 (HER2). HER2 is a transmembrane receptor that is overexpressed in some typ
Niraparib binds to the PARP enzyme and prevents it from repairing single-strand breaks in DNA. This causes the cancer cell's DNA to become more damaged, leading to cell death. Since cancer cells o
Pregabalin's precise mechanism of action is not fully understood, but studies suggest that it binds to the alpha2-delta subunit of voltage-gated calcium channels in the central nervous system. Thi
Sugammadex is a medication used to reverse the effects of certain muscle-relaxing drugs (rocuronium and vecuronium) during anaesthesia. It works by forming a complex with these drugs, neutralizing
Ramipril is an angiotensin-converting enzyme (ACE) inhibitor indicated for treating hypertension to lower blood pressure. ACE inhibitors inhibit the angiotensin-converting enzyme (ACE) actions, thereb
Azacitidine is a nucleoside metabolic inhibitor indicated to continue treating adult patients with acute myeloid leukemia. In addition, it is indicated for use in adult patients with acute myeloid leu
Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective peripheral H1-receptor antagonist activity. Fexofenadine Hydrochloride is indicated for:
Eribulin Mesylate (Halaven®) is a microtubule inhibitor indicated to treat patients with: Metastatic breast cancer who have previously received at least two chemotherapeutic regimens to treat
Dr. Reddy’s is well-positioned to support its API customers with APIs and services for peptides with extensive peptide therapeutics development capabilities, state-of-the-art process facilities supp
Semaglutide is a glucagon-like peptide 1 (GLP-1) receptor agonist, with 94% sequence homology to human GLP-1 indicated as an adjunct to diet and exercise to improve glycaemic control in adults wit
Enzalutamide is an androgen receptor inhibitor that acts on different steps in the androgen receptor signalling pathway. Enzalutamide has been shown to inhibit androgen binding to androgen receptors c
Olaparib is an inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, including PARP1, PARP2, and PARP3. PARP enzymes are involved in normal cellular homeostases, such as DNA transcription, cell cy
Bempedoic acid (Brand: Nexletol, Innovator: Esperion) is an essentially new, oral treatment option approved for patients needing further LDL-C lowering beyond maximally tolerated statin therapy. Bempe
Lumateperone is a serotonin 5HT2A receptor antagonist, a dopamine receptor phosphoprotein modulator (DPPM), and a serotonin transporter (SERT) inhibitor. Unlike existing schizophrenia treatments,
Siponimod is an oral, second-generation sphingosine-1-phosphate (S1P) receptor modulator. S1P receptor modulators can inhibit the egress and recirculation of lymphocytes from lymph nodes, a therap
In continuation to our efforts to understand the Azido impurities, we are evaluating the possibility of formation of two additional Azido impurities - Chloro methyl azido impurity and 4-Chloro azi
Nilotinib is an inhibitor of the BCR-ABL kinase. Nilotinib binds to and stabilizes the inactive conformation of the kinase domain of ABL protein. In vitro, Nilotinib inhibited BCR-ABL-mediated pro
Voriconazole (Vfend®) is an azole antifungal indicated for invasive aspergillosis candidemia (non- neutropenic) and disseminated candidiasis in skin, abdomen, kidney, bladder wall, and wounds, an
Linagliptin is an inhibitor of dipeptidyl peptidase-4 (DPP-4), an enzyme that degrades the incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP).
Ruxolitinib falls under the drug class known as Janus kinase inhibitors (JAK inhibitors). It is an inhibitor of the JAK1 and JAK2 protein kinases and works by competitively inhibiting the ATP-bind
Dutasteride inhibits the conversion of testosterone to dihydrotestosterone (DHT). DHT is the androgen primarily responsible for the prostate gland's initial development and subsequent enlargement.
Ibrutinib is a small-molecule inhibitor of Bruton's tyrosine kinase (BTK). Nonclinical studies show that ibrutinib can inhibit malignant B-cell proliferation and survival in vivo and cell migratio
